Sugi Predict

Sugi Predict / Compounds / SCHEMBL1104899

SCHEMBL1104899

SCHEMBL1104899

CCOC(=O)c1cn([C@H](CO)C(C)C)c2cc(OC)c(Cc3cccc(Cl)c3F)cc2c1=O

nearest known ligand 0.82

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ METTL3 Q86U44 1/20 0.82
▸ MAPT P10636 3/20 0.40
▸ ALDH1A1 P00352 3/20 0.40
▸ LMNA P02545 2/20 0.40
▸ TP53 P04637 1/20 0.37
▸ NR3C2 P08235 1/20 0.36
▸ POLB P06746 1/20 0.36
▸ GAA P10253 1/20 0.36
▸ KMT2A Q03164 1/20 0.35
▸ PDE3B Q13370 1/20 0.35
▸ PDE3A Q14432 1/20 0.35
▸ MRGPRX4 Q96LA9 1/20 0.35
▸ NPC1 O15118 1/20 0.35
▸ KDM4E B2RXH2 2/20 0.34
▸ HPGD P15428 2/20 0.34
▸ HSD17B10 Q99714 2/20 0.34
▸ EGFR P00533 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4360879 1.00 METTL3 (0.82) METTL3MAPTALDH1A1LMNATP53
SCHEMBL21104379 1.00 METTL3 (0.82) METTL3MAPTALDH1A1LMNATP53
SCHEMBL13942147 0.93 METTL3 (0.86) METTL3MAPTTP53GAAPDE3B
SCHEMBL13693054 0.93 METTL3 (0.86) METTL3MAPTTP53GAAPDE3B
SCHEMBL17549681 0.91 METTL3 (0.68) METTL3MAPTALDH1A1LMNANR3C2
SCHEMBL16385502 0.91 METTL3 (0.68) METTL3MAPTALDH1A1LMNANR3C2
Elvitegravir SCHEMBL726252 0.90 METTL3 (1.00) METTL3MAPTTP53POLBGAA
SCHEMBL1104875 0.90 METTL3 (0.88) METTL3MAPTGAAEGFR
Elvitegravir SCHEMBL13225651 0.90 METTL3 (1.00) METTL3MAPTTP53POLBGAA
Elvitegravir SCHEMBL726251 0.90 METTL3 (1.00) METTL3MAPTTP53POLBGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180265454-A1 Method for Producing 4-Oxoquinoline Compound JAPAN TOBACCO INC. (JP) 2018-09-20 — — US disclosed
EP-2190804-B1 PROCESS AND INTERMEDIATES FOR PREPARING INTEGRASE INHIBITORS GILEAD SCIENCES INC (US) 2015-11-18 — — EP disclosed
US-20150299104-A1 METHOD FOR PRODUCING 4-OXOQUINOLINE COMPOUND JAPAN TOBACCO INC (JP) 2015-10-22 — — US disclosed
US-20150299104-A1 METHOD FOR PRODUCING 4-OXOQUINOLINE COMPOUND JAPAN TOBACCO INC (JP) 2015-10-22 — — US disclosed
US-20150299104-A1 METHOD FOR PRODUCING 4-OXOQUINOLINE COMPOUND JAPAN TOBACCO INC (JP) 2015-10-22 — — US disclosed
EP-1992607-B9 METHOD FOR PRODUCING 4-OXOQUINOLINE COMPOUND JAPAN TOBACCO INC (JP) 2015-07-01 — — EP disclosed
EP-2069280-B1 Process and intermediates for preparing HIV integrase inhibitors GILEAD SCIENCES INC (US) 2015-03-25 — — EP disclosed
EP-1992607-B1 METHOD FOR PRODUCING 4-OXOQUINOLINE COMPOUND JAPAN TOBACCO INC (JP) 2014-12-31 — — EP disclosed
US-8796459-B2 Process and intermediates for preparing integrase inhibitors GILEAD SCIENCES, INC. (US) 2014-08-05 — — US disclosed
US-8796459-B2 Process and intermediates for preparing integrase inhibitors GILEAD SCIENCES, INC. (US) 2014-08-05 — — US disclosed
US-20090099366-A1 PROCESS AND INTERMEDIATES FOR PREPARING INTEGRASE INHIBITORS GILEAD SCIENCES, INC. (US) 2009-04-16 — — US disclosed
US-20090099366-A1 PROCESS AND INTERMEDIATES FOR PREPARING INTEGRASE INHIBITORS GILEAD SCIENCES, INC. (US) 2009-04-16 — — US disclosed
WO-2009036161-A1 PROCESS AND INTERMEDIATES FOR PREPARING INTEGRASE INHIBITORS GILEAD SCIENCES, INC. (US) 2009-03-19 — — WO disclosed
US-20090036684-A1 METHOD FOR PRODUCING 4-OXOQUINOLINE COMPOUND SHIONOGI & CO., LTD. (JP) 2009-02-05 — — US disclosed
US-20090036684-A1 METHOD FOR PRODUCING 4-OXOQUINOLINE COMPOUND SHIONOGI & CO., LTD. (JP) 2009-02-05 — — US disclosed
US-20090036684-A1 METHOD FOR PRODUCING 4-OXOQUINOLINE COMPOUND SHIONOGI & CO., LTD. (JP) 2009-02-05 — — US disclosed
EP-1992607-A1 METHOD FOR PRODUCING 4-OXOQUINOLINE COMPOUND Japan Tobacco, Inc. (JP) 2008-11-19 — — EP disclosed
US-20080125594-A1 PROCESS AND INTERMEDIATES FOR PREPARING INTEGRASE INHIBITORS GILEAD SCIENCES, INC. (US) 2008-05-29 — — US disclosed
US-20080125594-A1 PROCESS AND INTERMEDIATES FOR PREPARING INTEGRASE INHIBITORS GILEAD SCIENCES, INC. (US) 2008-05-29 — — US disclosed
WO-2008033836-A2 PROCESS AND INTERMEDIATES FOR PREPARING INTEGRASE INHIBITORS GILEAD SCIENCES, INC. (US) 2008-03-20 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090099366-A1 PROCESS AND INTERMEDIATES FOR PREPARING INTEGRASE INHIBITORS TYMS, TYMP, POLB METTL3 2511/4885MAPT 4249/4885ALDH1A1 2138/4885
US-20150299104-A1 METHOD FOR PRODUCING 4-OXOQUINOLINE COMPOUND IMPDH1, IMPDH2, CDK20 METTL3 938/4885MAPT 4278/4885ALDH1A1 2769/4885
US-20080125594-A1 PROCESS AND INTERMEDIATES FOR PREPARING INTEGRASE INHIBITORS TYMS, TYMP, POLB METTL3 2511/4885MAPT 4249/4885ALDH1A1 2138/4885
US-20180265454-A1 Method for Producing 4-Oxoquinoline Compound IMPDH1, IMPDH2, CDK20 METTL3 938/4885MAPT 4278/4885ALDH1A1 2769/4885
US-20090036684-A1 METHOD FOR PRODUCING 4-OXOQUINOLINE COMPOUND IMPDH1, IMPDH2, CDK20 METTL3 938/4885MAPT 4278/4885ALDH1A1 2769/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.